GlobeNewswire Inc.··NaKymera's Novel STAT6 Degrader Shows Promise in Skin and Lung Diseases
Kymera Therapeutics presented Phase 1b data for KT-621, demonstrating deep STAT6 degradation and favorable safety. Phase 2b trials in atopic dermatitis and asthma underway with results expected through late 2027.
KYMRatopic dermatitistype 2 inflammation